

LETTER TO THE EDITOR

Genomic Testing Access for Hearing Loss Must Catch Up to the Evidence

Emma McGonigal¹  | Andrew V. White^{2,3}  | Valerie Sung⁴ | Karen Liddle⁵ | Lilian Downie⁶ | Emily Shepard⁷

¹Western Australia Country Health Service, Derby, Western Australia, Australia | ²Townsville Hospital and Health Service, Townsville, Queensland, Australia | ³James Cook University, Townsville, Queensland, Australia | ⁴Centre for Community Child Health, Royal Children's Hospital, Melbourne, Victoria, Australia | ⁵Child Health Research Centre, University of Queensland, Brisbane, Queensland, Australia | ⁶Murdoch Children's Research Institute, Melbourne, Victoria, Australia | ⁷UsherKids Australia, Melbourne, Victoria, Australia

Correspondence: Emma McGonigal (emma.mcgonigal@gmail.com)

Received: 20 October 2025 | **Revised:** 15 December 2025 | **Accepted:** 12 January 2026

Keywords: congenital abnormalities | genetic counselling | genetic testing | hearing disorders

JEL Classification: Otorhinolaryngologic diseases, Medical genetics, Pediatric medicine

To the Editor,

Congenital hearing loss affects about 1–2 in every 1000 babies born in Australia [1]. Around 50% of childhood hearing loss has an underlying genetic cause [2]. To date, over 500 causative genetic variants are known to be responsible for both syndromic and non-syndromic hearing loss [3].

Genomic testing has revolutionised clinicians' ability to provide accurate and timely diagnosis for individuals with hearing loss and their families. Australia is at the forefront of demonstrating exome sequencing's cost-effective value in informing prognosis, guiding management and clarifying the risk of recurrence in family members [4]. This piece of evidence was successfully used to initiate Medicare funding for exome sequencing in childhood hearing loss, available since 2023 with Medicare Benefits Schedule (MBS) items 73,440–73,444.

Despite strong evidence of the benefit of genomic testing for these families, the combined uptake of these five MBS items—193 over 2 years—remains lower than the expected 180–200 per year and 3000 retrospectively eligible cases (Table 1). The available funding (\$1200 for singleton test) is insufficient for laboratories to complete testing (as of December 2025: Victorian Clinical Genetics Services, \$2195; Pathology Queensland,

\$2181), and testing processes are laboriously slow. In addition, there is limited access to genetic counselling, a vital service for families for adequate understanding and informed consent for testing. Genetics services often have long waitlists, inequitable and variable decisions about funded testing and a long wait for results. Consequently, most families are unable to realistically access genomic testing for hearing loss, and for those who can afford the test, the results may take several months. These delays mean that families might not receive results in time to inform reproductive decisions based on genetic risk or to plan early interventions for their infant, leaving them uninformed at a critical period. This situation reflects the broader challenge of MBS items in genomics (including paediatrics, renal, cardiac, neurology and cancer), whereby funding a test in isolation without considering staffing costs for laboratories, genetics services and patient perspectives has led to an implementation problem [7].

This frustrating gap and inequity in clinical care must be addressed.

We must ensure there is adequate funding, resources and training for laboratories to complete genomic testing for hearing loss and other conditions, and increase access to genetic counselling through training, funding and recognition of the profession's

TABLE 1 | Services Australia utilisation data for childhood hearing loss Medicare Benefits Schedule (MBS) items (November 2023–October 2025) [5, 6].

MBS item	Rebate	Services						Total
		State						
		NSW	VIC	QLD	SA	WA	TAS	
73,440 singleton	\$1200	55	23	4	29	20	2	133
73,441 trio	\$2100	0	16	3	0	0	0	19
73,442 reanalysis	\$500	1	0	0	0	0	0	1
73,443 cascade	\$400	34	0	0	5	0	0	39
73,444 reproductive partner	\$1200	1	0	0	0	0	0	1
Total		91	39	7	34	20	2	193

invaluable work. Most of all, we owe affected families equitable access to the opportunity for genomic testing to provide better, personalised and informed care.

Author Contributions

Emma McGonigal: writing – original draft and writing – review and editing. Andrew White: conceptualisation, supervision and writing – review and editing. Valerie Sung: supervision and writing – review and editing. Karen Liddle, Lilian Downie and Emily Shepard: writing – review and editing.

Funding

The authors have nothing to report.

Conflicts of Interest

Emma McGonigal is a volunteer advocate for the Usher Syndrome Coalition; she receives no financial remuneration for this role.

Data Availability Statement

The authors have nothing to report.

Emma McGonigal
Andrew V. White
Valerie Sung
Karen Liddle
Lilian Downie
Emily Shepard

References

1. C. C. Morton and W. E. Nance, “Newborn Hearing Screening—a Silent Revolution,” *New England Journal of Medicine* 354, no. 20 (2006): 2151–2164, <https://doi.org/10.1056/NEJMra050700>.
2. B. M. Ardle and M. Bitner-Glindzicz, “Investigation of the Child With Permanent Hearing Impairment,” *Archives of Disease in Childhood. Education and Practice Edition* 95, no. 1 (2010): 14–23, <https://doi.org/10.1136/adc.2008.150987>.
3. M. M. Li, A. A. Tayoun, M. DiStefano, et al., “Clinical Evaluation and Etiologic Diagnosis of Hearing Loss: A Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG),” *Genetics in Medicine* 24, no. 7 (2022): 1392–1406, <https://doi.org/10.1016/j.gim.2022.03.018>.

4. L. Downie, J. Halliday, R. Burt, et al., “Correction: Exome Sequencing in Infants With Congenital Hearing Impairment: A Population-Based Cohort Study,” *European Journal of Human Genetics* 29, no. 2 (2021): 363–596, <https://doi.org/10.1038/s41431-020-00750-4>.

5. Services Australia, “Statistics – Item Report [Internet],” accessed December 5, 2025, https://medicarestatistics.humanservices.gov.au/statistics/mbs_item.html.

6. Medical Services Advisory Committee, “Genetic Testing for Childhood Hearing Impairment [Internet],” (2024), accessed December 5, 2025, <https://www.msac.gov.au/applications/1680>.

7. C. Schilling, F. Sjaaf, I. Goranitis, et al., “Utilisation of Subsidised Genetic and Genomic Testing in a Publicly Funded Healthcare System 2014–2023,” *European Journal of Human Genetics* 33, no. 8 (2025): 1044–1050.